Previous 10 | Next 10 |
Emmaus Life Sciences ([[EMMA]]) announces that the Swiss Agency for Therapeutic Products has granted orphan drug status to Endari. Endari is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.The drug also enjoys Orph...
Endari® Granted Orphan Drug Status in Switzerland TORRANCE Calif. , Dec. 3, 2020 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in the treatment of sickle cell disease, announced today that the Swiss Agency for Therapeutic Products (Swissm...
Emmaus Life Sciences Submits Temporary License Application in Bahrain for Endari® PR Newswire TORRANCE, Calif., Nov. 10, 2020 TORRANCE, Calif. , Nov. 10, 2020 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in the treatment of s...
FDA Approves Updated Label for Endari® PR Newswire TORRANCE, Calif., Nov. 3, 2020 TORRANCE, Calif. , Nov. 3, 2020 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA) , a leader in sickle cell disease treatment, announced today revised prescri...
Emmaus Life Sciences ([[EMMA]] -5.7%) sells off its entire stake in South Korea-based Telcon RF Pharmaceutical as agreed upon last year for replacing the owned shares with the convertible bond collateral. Total net proceeds come to ~$36.6M (KRW 42B), out of which ~$25.1M w...
Emmaus Life Sciences Announces the Sale of its Telcon RF Pharmaceutical Inc. Shares PR Newswire TORRANCE, Calif., Oct. 14, 2020 TORRANCE, Calif. , Oct. 14, 2020 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in sickle cell d...
TORRANCE, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCPK: EMMA) , a leader in sickle cell disease treatment, announced today that it will hold an informational meeting of stockholders at which management will provide an update on recent sales activities ...
TORRANCE, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCPK: EMMA) , a leader in sickle cell disease treatment, announced today the submission of an application to the Saudi Food and Drug Authority (SFDA) for Marketing Authorization (MA) for Endari ® in the ...
TORRANCE, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCPK: EMMA) , a leader in sickle cell disease treatment, announced today the submission of an application to the Saudi Food and Drug Authority (SFDA) for Marketing Authorization (MA) for Endari ® in the ...
--Interim Analysis Indicates Decreased Number of Diverticula and Healthy Tissue-- TORRANCE, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCPK: EMMA) , a leader in sickle cell disease treatment, announced today preliminary top-line data for two patients who mo...
News, Short Squeeze, Breakout and More Instantly...
Emmaus Life Sciences Incorporation Company Name:
EMMA Stock Symbol:
NYSE Market:
Emmaus Life Sciences Incorporation Website:
Emmaus Life Sciences Announces Outcome of FDA Inspection of Postmarketing Adverse Drug Experience Compliance Program PR Newswire TORRANCE, Calif. , July 12, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCPK: EMMA) , a commercial-stage biopharmaceuti...
Emmaus Life Sciences Reports 2023 Financial Results PR Newswire TORRANCE, Calif. , July 3, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCPK: EMMA) , a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today r...
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...